Cargando…

Philadelphia-negative chronic myeloproliferative neoplasms

Chronic myeloproliferative diseases without the Philadelphia chromosome marker (Ph-), although first described 60 years ago, only became the subject of interest after the turn of the millennium. In 2001, the World Health Organization (WHO) defined the classification of this group of diseases and in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bittencourt, Rosane Isabel, Vassallo, Jose, Chauffaille, Maria de Lourdes Lopes Ferrari, Xavier, Sandra Guerra, Pagnano, Katia Borgia, Nascimento, Ana Clara Kneese, De Souza, Carmino Antonio, Chiattone, Carlos Sergio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Associação Brasileira de Hematologia e Hemoterapia 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3459391/ https://www.ncbi.nlm.nih.gov/pubmed/23049404 http://dx.doi.org/10.5581/1516-8484.20120034

Ejemplares similares

Inflammatory picture of Philadelphia-negative myeloproliferative neoplasms()
por: Pagnano, Katia Borgia Barbosa
Publicado: (2018)

Guideline on myeloproliferative neoplasms: Associacão Brasileira de Hematologia, Hemoterapia e Terapia Cellular: Project guidelines: Associação Médica Brasileira – 2019
por: Tavares, Renato Sampaio, et al.
Publicado: (2019)

Molecular biology of Philadelphia-negative myeloproliferative neoplasms
por: Campregher, Paulo Vidal, et al.
Publicado: (2012)

Guidelines on the treatment of acute myeloid leukemia: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular: Project guidelines: Associação Médica Brasileira – 2015
por: Bittencourt, Rosane, et al.
Publicado: (2016)

Guidelines for therapy of patients with chronic myeloproliferative neoplasms during the novel coronavirus SARS-CoV2 pandemic
por: Santos, Fabio Pires de Souza, et al.
Publicado: (2020)

Philadelphia-Negative Myeloproliferative Neoplasms Around the COVID-19 Pandemic
por: Barbui, Tiziano, et al.
Publicado: (2021)

Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation
por: Cacemiro, Maira da Costa, et al.
Publicado: (2018)

Effects of Mutational Combinations on Philadelphia-Negative Myeloproliferative Neoplasms
por: Ipek, Yonal-Hindilerden, et al.
Publicado: (2017)

Ocular Manifestations in Patients with Philadelphia-Negative Myeloproliferative Neoplasms
por: Liisborg, Charlotte, et al.
Publicado: (2020)

Philadelphia‐negative myeloproliferative neoplasms among Kuwaiti Nationals
por: Alshemmari, Salem, et al.
Publicado: (2020)

Splenic Infarction in Patients with Philadelphia-negative Myeloproliferative Neoplasms
por: Lee, Myung-Won, et al.
Publicado: (2022)

Applications of Artificial Intelligence in Philadelphia-Negative Myeloproliferative Neoplasms
por: Elsayed, Basel, et al.
Publicado: (2023)

Erratum on “Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation”
por: Cacemiro, Maira da Costa, et al.
Publicado: (2021)

Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms
por: Kaplan, Jason B., et al.
Publicado: (2016)

The Prognostic Role of Cytogenetics Analysis in Philadelphia Negative Myeloproliferative Neoplasms
por: Lanzarone, Giuseppe, et al.
Publicado: (2021)

The Role of Neutrophilic Granulocytes in Philadelphia Chromosome Negative Myeloproliferative Neoplasms
por: Kiem, Dominik, et al.
Publicado: (2021)

The clinical role of interferon alpha in Philadelphia-negative myeloproliferative neoplasms
por: Yoon, Seug Yun, et al.
Publicado: (2021)

Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms
por: Stuckey, Ruth, et al.
Publicado: (2023)

A Survey Conducted during COVID-19 Pandemic Among Brazilian Chronic Myeloid Leukemia and Philadelphia-Negative Myeloproliferative Neoplasms Patients
por: Fechio, Leonardo, et al.
Publicado: (2021)

Philadelphia-negative myeloproliferative neoplasms display alterations in monocyte subpopulations frequency and immunophenotype
por: Bassan, Vitor Leonardo, et al.
Publicado: (2022)

Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms
por: Holmström, Morten Orebo, et al.
Publicado: (2020)

Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms
por: Mora, Barbara, et al.
Publicado: (2022)

The Genomic Landscape in Philadelphia-Negative Myeloproliferative Neoplasm Patients with Second Cancers
por: Hsu, Chia-Chen, et al.
Publicado: (2022)

Acquired von willebrand syndrome in patients with Philadelphia-negative myeloproliferative neoplasm
por: Song, Ik-Chan, et al.
Publicado: (2023)

Bone Marrow Soluble Mediator Signatures of Patients With Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
por: Cominal, Juçara Gastaldi, et al.
Publicado: (2021)

Marrow iron staining should always be performed to diagnose Myelodysplastic/myeloproliferative neoplasia with ring sideroblasts and thrombocythemia.
por: Chauffaille, Maria de Lourdes Lopes Ferrari, et al.
Publicado: (2019)

Trends and Inpatient Outcomes of Venous Thromboembolism-Related Admissions in Patients with Philadelphia-Negative Myeloproliferative Neoplasms
por: Katiyar, Vatsala, et al.
Publicado: (2019)

Bone marrow megakaryocytic activation predicts fibrotic evolution of Philadelphia-negative myeloproliferative neoplasms
por: Schino, Mattia, et al.
Publicado: (2020)

Bcl‐xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms
por: Petiti, Jessica, et al.
Publicado: (2020)

Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms
por: Pandey, Ruchi, et al.
Publicado: (2015)

Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors
por: Helbig, Grzegorz
Publicado: (2018)

Organ Stiffness in the Work-Up of Myelofibrosis and Philadelphia-Negative Chronic Myeloproliferative Neoplasms
por: Benedetti, Edoardo, et al.
Publicado: (2020)

Myelofibrotic and leukemic transformation in 2016 WHO-defined Philadelphia-negative myeloproliferative neoplasm
por: Song, Ik-Chan, et al.
Publicado: (2022)

CCL2 rs1024611Gene Polymorphism in Philadelphia-Negative Myeloproliferative Neoplasms
por: Hodeib, Hossam, et al.
Publicado: (2022)

PB2054: HIP AND KNEE OSTEOARTHRITIS IN PHILADELPHIA CHROMOSOME-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
por: Holik, H., et al.
Publicado: (2022)

P1020: SCREENING FOR PORTAL HYPERTENSION IN PATIENTS WITH PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
por: Davidson, M., et al.
Publicado: (2022)

Diversity of breakpoints of variant Philadelphia chromosomes in chronic myeloid leukemia in Brazilian patients
por: Chauffaille, Maria de Lourdes Lopes Ferrari, et al.
Publicado: (2015)

Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios
por: Palandri, Francesca, et al.
Publicado: (2021)

Platelets Contribution to Thrombin Generation in Philadelphia-Negative Myeloproliferative Neoplasms: The “Circulating Wound” Model
por: Lucchesi, Alessandro, et al.
Publicado: (2021)

The Outcome of Fatherhood in Patients With Philadelphia-Negative Myeloproliferative Neoplasms: A Single-Institution Experience
por: Ali, Elrazi A, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4mucgn8k0h0tor5pno0stttofv